Charles Zhu
Stock Analyst at Guggenheim
(2.43)
# 2,502
Out of 5,140 analysts
20
Total ratings
47.06%
Success rate
16.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $12.51 | -4.08% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $13.72 | +60.35% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $2.59 | - | 1 | Dec 13, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.75 | +587.68% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $109.04 | -48.64% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.77 | +281.28% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $39.90 | -34.84% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $36.01 | -11.14% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $23.93 | -41.50% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $12.51
Upside: -4.08%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $13.72
Upside: +60.35%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.59
Upside: -
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.75
Upside: +587.68%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $109.04
Upside: -48.64%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.77
Upside: +281.28%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $39.90
Upside: -34.84%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $36.01
Upside: -11.14%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $23.93
Upside: -41.50%